This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Drugs used in asthma

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The drugs used in the management of asthma fall into two broad categories:

  • controllers
  • aim is to control clinical symptoms, and reduce future risks such as exacerbations and decline in lung function
  • taken daily on long term basis
  • agents include:
    • inhaled and systemic corticosteroids
    • cromones
    • leukotriene antagonists
    • methotrexate
    • long acting inhaled beta-adrenergic agonists in combination with inhaled corticosteroids
  • relievers:
    • aim is to reverse bronchoconstriction and relieve the symptoms quickly
    • used on as needed basis
    • agents include:
      • rapid acting inhaled beta-adrenergic agonists
      • short acting theophylline
      • inhaled anticholinergics
      • short acting oral beta-adrenergic agonists

Note:

  • before initiating a new drug therapy, practitioners should check adherence with existing therapies, inhaler technique and eliminate trigger factors
  • β-blockers, including eye drops, are contraindicated in patients with asthma (2)

Reference:

  1. Global Initiative For Asthma (GINA) 2023. Global strategy for asthma management and prevention
  2. British Thoracic Society (BTS)/Scottish Intercollegiate Guidelines Network (SIGN) 2019. British Guideline on the Management of Asthma. A national clinical guideline.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.